Tidal Trust II Nicholas Global Equity and Income ETF (ARCA: GIAX)

Latest news for Tidal Trust II Nicholas Global Equity and Income ETF (ARCA:GIAX)

The Fund is an actively managed exchange-traded fund (ETF) that primarily seeks to generate current income. The Funds strategy includes two components as (i) holding shares of unaffiliated passively managed ETFs that seek to provide exposure to a range of global equity securities (Index ETFs) and (ii) selling daily index credit call spreads (Index Call Spreads) on one or more US equity indices. In addition, in some instances, the Fund may invest in individual securities rather than an Index ETF (as described below). The Fund will also hold U.S. Treasury securities. The Funds daily credit call spread strategy consists of selling a call option and simultaneously buying another call option at a higher strike price for income generation.

Nicholas Global Equity and Income ETF

Tidal Trust II Nicholas Global Equity and Income ETF

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for Paylocity Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) from $171 to $182. Keybanc analyst Jason Celino maintained an Overweight rating. Paylocity shares fell 1.3% to close at $162.87 on Tuesday. <a href="https://www.benzinga.com/quote/pcty/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird increased the price target for Acuity Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) from $280 to $318. Baird analyst Timothy Wojs maintained a Neutral rating. Acuity Brands shares gained 8.7% to close at $299.35 on Tuesday. <a href="https://www.benzinga.com/quote/AYI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised The Marcus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) price target from $18 to $20. Benchmark analyst Mike Hickey maintained a Buy rating. Marcus shares gained 0.5% to close at $15.15 on Tuesday. <a href="https://www.benzinga.com/quote/MCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) price target from $130 to $107. B of A Securities analyst Heather Balsky downgraded the stock from Buy to Neutral. PVH shares fell 3.2% to close at $97.64 on Tuesday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets raised Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $270 to $400. Northland Capital Markets analyst Nehal Chokshi upgraded the stock from Market Perform to Outperform. Salesforce shares fell 1% to close at $270.87 on Tuesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group raised the price target for M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from $187 to $210. Evercore ISI Group analyst John Pancari upgraded the stock from In-Line to Outperform. M&amp;T Bank fell 3% to close at $172.72 on Tuesday. <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $515 to $520. Morgan Stanley analyst Brian Harbour maintained an Overweight rating. Domino&#8217;s shares gained 0.1% to close at $430.66 on Tuesday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) from $121 to $127. Piper Sandler analyst John Barnidge maintained a Neutral rating. Prudential Financial shares fell 1.4% to close at $119.36 on Tuesday. <a href="https://www.benzinga.com/quote/PRU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna boosted Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) price target from $250 to $260. Susquehanna analyst Bascome Majors maintained a Neutral rating. Union Pacific shares fell 0.4% to close at $245.55 on Tuesday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $104 to $100. B of A Securities analyst Lorraine Hutchinson maintained a Buy rating. NIKE shares gained 0.8% to close at $89.13 on Tuesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>. </li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PCTY

Nike To $100? Here Are 10 Top Analyst Forecasts For Wednesday

Truist Securities analyst Mark Hughes maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Buy and raises the price target from $335 to $365.

Truist Securities Maintains Buy on Willis Towers Watson, Raises Price Target to $365

WIIM

TSLA

Tesla shares are trading lower after the company reported Q3 delivery and production figures.

<ul>
<li>Third-quarter 2024 total U.S. sales decreased 20%&nbsp;year over year</li>
<li>Company's total share grows in consecutive months during Q3, from 7.2% in July to 8% in September</li>
<li>During the company's third quarter, inventory was reduced by 50K units (-11.6%)</li>
<li>Incentive offerings to continue through the end of the year across the U.S. brand portfolio, including Chrysler, Dodge, FIAT, Jeep&#xAE; and Ram</li>
<li>Jeep Wrangler 4xe, Jeep Grand Cherokee 4xe, Dodge Hornet R/T and Chrysler Pacifica Hybrid take four of top-five spots for best-selling hybrids in the U.S. (source: S&amp;P Global Mobility U.S. State Registrations database through July 31, 2024)</li>
</ul>
FCA US LLC reports total sales of 305,294 vehicles in the third quarter of 2024. Overall, third-quarter 2024 total U.S. sales declined 20% year over year. Total market share increased month over month during the third quarter from 7.2% in July to 8% in September while inventory was reduced by 50K units (-11.6%).

Earnings

STLA

FCA Reports Q3 2024 Total U.S. Sales Decreased 20% Year Over Year; Reports Total Sales Of 305,294 Vehicles; Total Market Share Increased MoM During Q3 From 7.2% In July To 8% In September While Inventory Was Reduced By 50K Units

JP Morgan analyst John Royall downgrades PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) from Overweight to Neutral and lowers the price target from $53 to $40.

Downgrades

JP Morgan Downgrades PBF Energy to Neutral, Lowers Price Target to $40

Truist Securities analyst Youssef Squali maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and raises the price target from $108 to $120.

Truist Securities Maintains Buy on Trade Desk, Raises Price Target to $120

Guidance

MULN

Mullen Expects Q3 2024 Revenue Of $4.5M; Plans Further Cash Burn Reductions Through 2025 With Target To Achieve Cash Breakeven By December 2025

Jim Cramer is sounding the alarm, but not in the way you might expect. For those bullish on Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Cramer's latest take might be <a href="https://www.benzinga.com/topic/jim-cramer">hard to swallow</a>.
<h2 class="wp-block-heading">Hot Money Streaming Out Of Nvidia, Apple</h2>
In a tweet, Cramer said, &#8220;The hot money is streaming out of Nvidia and Apple and into China. Let it stream. Do not defend these now. Let this money leave. On China only BABA has actual fundamentals if you must&#8230; But let it rain here. Get all of these short Nvidia options and ETFs to play out.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The hot money is streaming out of Nvidia and Apple and into China. Let it stream. Do not defend these now. Let this money leave. On China only BABA has actual fundamentals if you must.. But let it rain here. Get all of these short Nvidia options and etfs to play out..
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1841411620481663388?ref_src=twsrc%5Etfw">October 2, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The reasoning? Cramer hints that Nvidia's sky-high valuations and Apple's post-iPhone slump might leave them vulnerable to short-term pain. If you&#8217;re holding Nvidia options or ETFs, Cramer believes you might want to ride the short wave. 
Cramer&#8217;s suggestion is a subtle signal that a pullback could be looming, especially as investor sentiment shifts and valuations begin to look more stretched than a Friday-night binge-watch.
The GraniteShares 2x Short NVDA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVD#NASDAQ">NVD</a>) and the Direxion Daily NVDA Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>) are inverse ETFs positioned to gain on Nvidia stock&#8217;s underperformance. Investors in the Direxion Daily AAPL Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPD#NASDAQ">AAPD</a>) gain when Apple shares underperform.
Read Also: <a href="https://www.benzinga.com/government/24/10/41127863/despite-nvidia-selloff-bidens-law-and-taiwan-semis-advantage-offer-growth-potential">Despite Nvidia Selloff, Biden&#8217;s Law and Taiwan Semi&#8217;s Advantage Offer Growth Potential</a>
<h2 class="wp-block-heading">Only Alibaba Has Actual Fundamentals, Says Jim Cramer</h2>
Meanwhile, where should the more adventurous traders look? According to Cramer, only one Chinese juggernaut is worth considering amid the capital outflows into China: Alibaba Group Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>). 
The e-commerce giant, despite facing regulatory hurdles, is backed by solid fundamentals. The GraniteShares 2x Long BABA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BABX#NASDAQ">BABX</a>) provides leveraged exposure to Alibaba shares. Other ETFs with substantial allocation to Alibaba shares in their portfolio include the iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) (8.96% Alibaba stock), iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) (9.03% Alibaba stock) and the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) (11.05% allocation to Alibaba stock).
If you must dip into the Chinese markets, BABA might be your best bet—just don't expect smooth sailing.
Cramer's latest recommendation suggests patience with Nvidia and Apple, letting short sellers have their moment, and keeping a cautious but interested eye on Alibaba's potential for a rebound.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41135385/nasdaq-ends-1-5-lower-as-tesla-nvidia-and-apple-fall-investor-optimism-declines-fear-index-remains-">Nasdaq Ends 1.5% Lower As Tesla, Nvidia, And Apple Fall: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Asia

Long Ideas

Short Sellers

Short Ideas

Tech

AAPD

AAPL

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

BABX

KWEB

MCHI

NVDA

NVDD

Cramer Says 'Hot Money' Flowing From Nvidia, Apple Into China, Focus On Alibaba 'If You Must'

JP Morgan analyst John Royall upgrades Par Pacific Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PARR#NYSE">PARR</a>) from Neutral to Overweight and lowers the price target from $36 to $30.

Upgrades

PARR

JP Morgan Upgrades Par Pacific Hldgs to Overweight, Lowers Price Target to $30

Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases &nbsp;
Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective&nbsp;October 3rd
WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- &nbsp;Eliem Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>), announced today that it will change its corporate name to Climb Bio, Inc. The new name and corporate brand reflect the Company's new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol "CLYM" on the Nasdaq Global Market at the open of the market on October 3, 2024.

ELYM

Eliem Therapeutics Announces Rebranding And Corporate Name Change To Climb Bio, Inc., Will Begin Trading On Nasdaq Under The Trading Symbol "CLYM" Effective October 3rd

Truist Securities analyst Joseph Civello maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Hold and lowers the price target from $85 to $83.

Truist Securities Maintains Hold on Nike, Lowers Price Target to $83

RPM International Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) shares are trading higher after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41137296/rpm-reports-record-fiscal-2025-first-quarter-results" rel="noreferrer noopener">reported&nbsp;first-quarter results</a>.
Sales declined 2.1% Y/Y to $1.97 billion, missing the consensus of $2.015 billion. Despite volume growth at CPG and PCG and modestly positive pricing, foreign currency headwinds and volume declines at Consumer Group and SPG outweighed these gains.
Geographically, sales declined slightly in North America, while European sales were impacted by a weak economic environment, foreign currency headwinds, and divestitures.
Emerging markets, especially Latin America, faced foreign currency challenges, but sales grew in Asia/Pacific and Africa/Middle East, driven by infrastructure spending and high-performance building projects.
Adjusted EPS was $1.84,<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> beating the consensus of $1.75</a>.
In the quarter, operating cash flow stood at&nbsp;$248.1 million,&nbsp;led by higher profitability and improved working capital management.
As of August-end, total liquidity, comprising cash and committed revolving credit facilities, reached $1.44 billion, up from $1.23 billion a year ago.
The company returned&nbsp;$76.4&nbsp;million&nbsp;to stockholders through cash dividends and share repurchases.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41135395/rpm-international-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most" rel="noreferrer noopener">RPM International Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Outlook:&nbsp;For&nbsp;the second quarter, the company expects sales to be flat Y/Y and adjusted EBIT to&nbsp;increase in the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">mid-single-digit&nbsp;percentage&nbsp;range Y/Y.</a>
For FY25, the company continues to expect sales growth in the low-single-digit percentage range Y/Y and adjusted EBIT increase in the mid-single- to low-double-digit percentage range Y/Y.
Frank C. Sullivan, RPM chairman and CEO said, &#8220;The economic outlook for the second quarter remains mixed with continued growth in high-performance building construction and renovation, and softness in residential end markets.&#8221;
&#8221;While we are optimistic that lower interest rates will eventually lead to a rebound in residential markets, it is too early to say precisely when growth will return. As we have demonstrated, no matter the economic backdrop, we will focus on controlling what we can, including executing on MAP 2025 initiatives to leverage the power of RPM to capture growth opportunities, expand margins and structurally improve cash flow.&#8221;
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P MidCap 400 Dividend Aristocrats ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/REGL#BATS">REGL</a>) and First Trust Dividend Strength ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDS#NASDAQ">FTDS</a>).
Price Action: RPM shares are up 2.42% at $123.00&nbsp;premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41137481/nasdaq-s-p-futures-sag-as-downside-risks-intensify-oil-spikes-nike-slides-why-this-strategist-is-ex" target="_blank" rel="noreferrer noopener">Nasdaq, S&amp;P Futures Sag As Downside Risks Intensify, Oil Spikes, Nike Slides: Why This Strategist Is Expecting &#8216;Stronger&#8217; Second-Half Of October</a></li>
</ul>

Equities

Large Cap

Movers

FTDS

REGL

Specialty Coatings Company RPM Defies Market Pressure: EPS Beats Despite Sales Slump And Global Headwinds

Government

Regulations

ZENA

ZenaTech Announces FAA Approval For Evaluation, Testing And Demonstration Of ZenaDrone Drone Solutions In U.S.

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA&#xAE; reduced risk of death by 23 percent at 24 months compared to enzalutamide
LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA&#xAE; (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268936-1&amp;h=3004083318&amp;u=https%3A%2F%2Fecop.events%2Fwp-content%2Fuploads%2F2024%2F09%2FClinical_evaluation.pdf&amp;a=Abstract+%23P31">Abstract #P31</a>), this study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The study applied U.S. Food and Drug Administration (FDA) real-world evidence guidance and employed robust methodology, data sources and a large, diverse cohort to ensure validity of its findings. The retrospective study identified mCSPC patients who initiated ERLEADA&#xAE; or enzalutamide between December 16, 2018 – December 31, 2023, based on patient data in electronic databases. There were 1,800 ERLEADA&#xAE; and 1,909 enzalutamide initiators who met study criteria.
The analysis demonstrated patients with mCSPC who initiated ERLEADA&#xAE; as their first ARPI had a statistically significant 23 percent reduction in their risk of death at 24 months compared to patients who initiated on enzalutamide (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62-0.96;&nbsp;P&lt;0.019). The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA&#xAE; cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent).1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA&#xAE; plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median 22.7 months of follow-up (HR 0.67; 95% CI, 0.51-0.89;&nbsp;P=0.005) and at the final analysis after a median 44 months of follow-up (HR 0.65; 95% CI, 0.53-0.79;&nbsp;P&lt;0.0001).1,2

Biotech

General

Johnson & Johnson Presents Results From Study Showing That ERLEADA Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival Compared To Enzalutamide In Patients With Metastatic Castration-sensitive Prostate Cancer

Truist Securities analyst William Stein reiterates Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and raises the price target from $918 to $994.

Reiteration

MPWR

Truist Securities Reiterates Buy on Monolithic Power Systems, Raises Price Target to $994

MIT Federal Credit Union (MIT FCU), a full-service, Massachusetts-based credit union serving over 35,000 members, has announced a new partnership with Upstart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), the leading artificial intelligence (AI) lending marketplace, to provide personal loans to new and existing members.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20241002015433/en/">https://www.businesswire.com/news/home/20241002015433/en/</a>

UPST

MIT Federal Credit Union Selects Upstart For Personal Lending

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) is losing a <a href="https://www.benzinga.com/quote/NNE/news">&#8220;lot of money.&#8221;</a>
On Oct. 1, NANO Nuclear Energy said Carlos O. Maidana has been named as the company&#8217;s head of thermal hydraulics and space program.
Cramer recommended buying McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>). &#8220;I'm ready to start buying, don't buy all at once.&#8221;
On Sept. 25, Deutsche Bank analyst George Hill maintained McKesson with a Buy and lowered the price target from $623 to $579.
Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is a &#8220;little too much oil for me," Cramer said.
On Oct 1, Wells Fargo analyst Roger Read maintained Diamondback Energy with an Overweight and lowered the price target from $230 to $219.
&#8220;It's got a huge multiple for its growth rate, and that is worrisome to me. I'm going to have to say we got to come back with something that is less expensive,&#8221; Cramer said when asked about Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>).
On Aug. 29, Baird analyst Luke Junk maintained Littelfuse with an Outperform and raised the price target from $300 to $315.
Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) is a &#8220;value trap,&#8221; Cramer said.
On Sept. 9, UBS analyst Manav Gupta maintained Archer-Daniels Midland with a Neutral and raised the price target from $60 to $64.
Price Action:
<ul>
<li>NANO Nuclear Energy shares gained 14.8% to settle at $16.54 on Tuesday.</li>
<li>McKesson shares gained 0.8% to close at $498.48 during the session.</li>
<li>Diamondback shares gained 3% to close at $177.52 during Tuesday's session.</li>
<li>Littelfuse shares fell 1.7% to settle at $260.64 on Tuesday.</li>
<li>Archer-Daniels-Midland shares fell 0.4% to close at $59.52 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>
Image: Shutterstock

Media

FANG

LFUS

Jim Cramer: This Consumer Defensive Stock Is A Buy, Archer-Daniels-Midland Is A 'Value Trap'

QCOM

'Qualcomm Is Unlikely To Introduce The Next Generation Of Its Flagship PC Processor Until At Least The Second Half Of 2025, According To Industry Sources' - DigiTimes Alert

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) with a Buy and raises the price target from $10 to $12.

AMRX

Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $12

JP Morgan analyst Marcelo Santos downgrades MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) from Overweight to Neutral and maintains the price target from $2400 to $2400.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Tidal Trust II Nicholas Global Equity and Income ETF

News

Latest news for Tidal Trust II Nicholas Global Equity and Income ETF (ARCA:GIAX)